Develops molecular diagnostic tests for organ transplant rejection.
Jun 2026Revenue $1.67M/yrExpenses $52.0M/yr
No trendCash runway ≈ 7 months from Jun 2026
Figures by year
When will Insight Molecular Diagnostics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $1.67M and expenses $52.0M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $4.05M | $55.2M | −$51.1M |
| Dec 2024 | $1.88M | $62.9M | −$61.0M |
| Dec 2023 | $1.50M | $26.6M | −$25.1M |
| Dec 2022 | $958K | $19.0M | −$18.0M |
| Dec 2021 | $2.20M | $55.9M | −$53.7M |
| Dec 2020 | $1.22M | $30.9M | −$29.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.